Table 1.
Preferential effect by multisubtype IFN-α treatment on late mortality in patients with melanoma
| Average mortality (95 % CI) | Estimated 9-year OS (% ± SE) | p value 9-year OS | p value logrank | ||
|---|---|---|---|---|---|
| Follow-up 0–3 years | Follow-up >3 years | ||||
| All patients, treated (n = 128) | 12.3 (9.0–16.7) | 3.2 (1.8–5.4) | 57.6 ± 4.5 | 0.012 | 0.052 |
| All patients, controls (n = 124) | 11.5 (8.3–15.9) | 9.3 (6.7–13.0) | 41.7 ± 4.5 | ||
| Stage 3b, treated (n = 54) | 21.6 (14.7–31.7) | 2.2 (0.7–7.0) | 45.9 ± 6.9 | 0.009 | 0.143 |
| Stage 3b, controls (n = 52) | 17.9 (11.8–27.2) | 16.3 (10.3–25.9) | 22.1 ± 6.0 | ||
The table shows mortality per 100 person-years with 95 % confidence intervals by follow-up time interval and treatment arm, in the trial on the effect of adjuvant therapy of melanoma with natural, multisubtype IFN-α performed by Stadler et al. [8]. Early and late mortality was arbitrarily defined as occurring before and after 3 years of follow-up, respectively